Vancomycin-Resistant Enterococci

Publisher Website
Google Scholar
Abstract
Vancomycin-resistant enterococci infections have emerged as an important cause of hospital-acquired infections. The main risk factors are prolonged and multiple hospital admissions, reduced immunity and invasive procedures. The beneficial effect of screening and isolating colonized patients is unclear, and local hospital policy should be followed. The main treatment options are daptomycin and linezolid. Higher daptomycin doses are indicated for MIC between 3 and 4 mg/L, and synergism has been demonstrated for amoxicillin and rifampicin. Linezolid is an alternative which can be given intravenously and orally.